Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04861766
Other study ID # VIV-STYL-L-01
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date May 6, 2021
Est. completion date March 31, 2023

Study information

Verified date April 2023
Source Laboratoires Vivacy
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a safety and efficacy study of STYLAGE® Lin Chinese adults with Nasolabial Folds.


Description:

This is a prospective, multi-center, parallel-group, subject and evaluator-blinded, randomized controlled trial to demonstrate the non-inferiority of the study device, STYLAGE® L, when compared to an active comparator for the correction of moderate and severe NLFs. Subjects will randomly receive STYLAGE® L or the active comparator (ratio 1:1) injection in the NLFs at first visit on Day 0. Proportion of subjects having a NLFs severity improvement (blinded evaluation), 6 months after treatment initiation will be assessed and compared between the two groups. This will also be done during the other visits (1, 3, 9 and 12 months after treatment initiation). Global aesthetic improvement according to blinded independent evaluator and subject, subjects' satisfaction, and safety parameters will also be assessed during the study period.


Recruitment information / eligibility

Status Completed
Enrollment 390
Est. completion date March 31, 2023
Est. primary completion date August 16, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Men and women aged = 18 years. 2. Chinese ethnicity. 3. Subjects who wanting to correct his/her nasolabial folds 4. Subjects with moderate to severe nasolabial folds (attaining grade 3 on both side or 4 on both side) in the WSRS of nasolabial fold, per assessment of the Blinded Evaluator. 5. Subjects willing to abstain from other facial plastic surgical or cosmetic procedures during the study period. 6. Subjects with realistic expectations who can understand and comply with the instructions and all visit schedule. 7. Women of childbearing potential (WOCBP) who agree contraception during the study period. 8. Subjects who voluntarily decided the participation of the study and signed the informed consent. 9. Being able to stand mild pain. Exclusion Criteria: 1. Subjects who are contraindicated to augmentation with HA fillers 2. Subjects who had a history of keloid formation or hypertrophic scar 3. Subjects presenting a scar or skin disorder (i.e. active dermal disease [facial psoriasis, eczema, rosacea, perioral dermatitis, acne, herpes, etc], inflammation or an unhealed wound) below the level of the lower orbital rim that may confound the study evaluation 4. Has ever received semi-permanent fillers or permanent facial implants (eg, calcium hydroxyapatite, poly-L-lactic acid, polymethylmethacrylate, silicone, expanded polytetrafluoroethylene) anywhere below the inferior orbital rim, or is planning to be implanted with any of these products at any time during the study 5. Has undergone temporary dermal filler treatment (e.g., hyaluronic acid or collagen) below the inferior orbital rim within 12 months before enrollment or is planning to undergo such treatment during the study 6. Has undergone facial tissue augmentation with fat injections, botulinum toxin injections, mesotherapy, or cosmetic facial procedures (eg, facial liposuction, aesthetic surgery, face-lift, photomodulation, intense pulsed light, radio frequency, dermabrasion, laser or chemical peel, or other ablative procedures) below the inferior orbital rim within 6 months before enrollment or is planning to undergo any such treatment during the study 7. Subjects who has any history of severe multiple allergies or an allergy resulting in anaphylaxis, or an allergy to hyaluronic acid and/or one of the ingredients of the study products 8. Subject is pregnant or planning to be pregnant during the study period or lactating. Women of childbearing potential who have a positive pregnancy test result during screening. Women of childbearing potential who are unwilling to use effective birth control measures during the full course of the study 9. Subject suffering from a serious or progressive disease, which, in the Investigator's judgment, put the subject at undue risk for participation in this clinical trial (i.e. cancer or pre-cancer, immunocompromised, uncontrolled diabetes, epilepsy, severe cardio-cerebrovascular disease(s) (i.e. stroke, idiopathic aortic stenosis, aneurysm, hypertrophic obstructive cardiomyopathy, ischaemic heart disease, tachyarrhythmias, severe heart failure [classified as NYHA III-IV], etc), , etc.) 10. Subject having a history of cancer within 5 years 11. Subjects who received oral surgery (eg. tooth extraction, orthodontia or implantation) within 6 weeks before enrollment or is planning to undergo any of these procedures during the study 12. Subject has history or active autoimmune disease (e.g. inflammatory bowel disease), active or history of connective tissue disease (rheumatoid arthritis, scleroderma, and systemic lupus erythematosus) 13. Subjects with current or a history of hemorrhagic diseases 14. Subject who received chemotherapy, immunosuppressive agents, immunomodulatory therapy (e.g. monoclonal antibodies), systemic corticosteroids within 3 months (inhaled corticoids are allowed). 15. Subjects unlikely to achieve a meaningful aesthetic result with the prescribed dosage regimen of the study product per Investigator's judgement 16. Subjects who participated in other clinical trial within 30 days or who is in an exclusion period of one. 17. Subjects with uncontrolled hypertension (systolic blood pressure above 160mmHg or diastolic blood pressure above 100 mmHg at resting status), and/or significant liver (serum ALT or AST =2X the upper limit of the reference range), kidney (BUN, Urea or Cr=1.5X the upper limit of the reference range), and/or blood coagulation (PT, or APTT, or INR> 20% of the reference range) disorders per judgement of the Investigator. 18. Current or a history of alcoholism, drug abuse, or drug dependence. 19. Subject who had been deprived of their freedom by administrative or legal decision or who is under guardianship 20. Subject with a past history of streptococcal disease (manifested by recurrent sore throat or acute rheumatic fever) or with an active infection to streptococcus 21. Has facial hair (e.g., beards, sideburns, etc.), piercing or tattoo in the area to be treated that would interfere with investigation assessments and create inconsistency in required investigation photography during the study period 22. Personnel of the study department, close relatives of the study department personnel (i.e. parents, children, siblings, or spouse), employees, or close relatives of employees at the Sponsor or CRO company. 23. Other conditions the Investigator considers inappropriate for enrollment

Study Design


Related Conditions & MeSH terms


Intervention

Device:
STYLAGE® L
Injection in both NLFs
Active Comparator
Injection in both NLFs

Locations

Country Name City State
China Air Force Medical Center, PLA Beijing Haidian District
China Beijing Hospital Beijing Dong Cheng District
China Peking University First Hospital Beijing Xicheng District
China Peking University Third Hospital Beijing Haidian District
China West China Hospital of Stomatology Sichuan University Chengdu Sichuan
China West China Hospital Sichuan University Chengdu Sichuan
China Guangdong Second Provincial General Hospital Guangzhou Guangdong
China SUN YAT-SEN Memorial Hospital, SUN YAT-SEN University Guangzhou Guangdong

Sponsors (1)

Lead Sponsor Collaborator
Laboratoires Vivacy

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary WSRS improvement Percentage of responders, defined by at least 1-point improvement from baseline 5-point WSRS, as measured by the Blinded Evaluator at 6 months after last treatment for both groups. Month 6
Secondary WSRS improvement Percentage of responders, defined by at least 1-point improvement from baseline 5-point WSRS, as measured by the Blinded Evaluator 1, 3, 9, and 12 months
Secondary GAIS assessment Percentage of responders, defined by having "Improved", "Much improved" or "Very much improved" according to the Global Aesthetic Improvement Scale (GAIS), as assessed by the subject and the Treating Investigator 1, 3, 9, and 12 months
Secondary Subject satisfaction assessment Percentage of satisfied subjects on each question of the subject satisfaction assessment 1, 3, 6, 9, and 12 month
Secondary Device performance Results of device performance evaluation after the initial and touch-up injection, respectively, by the Treating Investigator for both groups. initial and touch up
Secondary Report of Adverse Event Product safety will be assessed by collection of local tolerability after each injection session, and Adverse Events (AEs) throughout the study. Day 0, Month 1, Month 3, Month 6, Month 9, Month 12
See also
  Status Clinical Trial Phase
Completed NCT05433233 - Effects of Lifestyle Walking on Blood Pressure in Older Adults With Hypertension N/A
Recruiting NCT06032065 - Sequential Multiple Assessment Randomized Trial of Exercise for PAD: SMART Exercise for PAD (SMART PAD) Phase 3
Completed NCT05293730 - Trial of the Impact of the Electronic Frailty Integrated With Social Needs N/A
Recruiting NCT03932162 - Gene Expression Changes In Young and Geriatric Skin Early Phase 1
Completed NCT04064528 - Effects of Age on Amino Acid Delivery to Tendon N/A
Completed NCT03366129 - Blood-Brain Barrier Disruption in People With White Matter Hyperintensities Who Have Had a Stroke
Completed NCT06029920 - Influence of Overground Walking on Biomarkers, Cognitive Function, and Quality of Life in Elderly With Mild Cognitive Impairment N/A
Recruiting NCT05566938 - Study to Design a Precision Nutrition Strategy at a Group Level in the Elderly N/A
Recruiting NCT05543980 - Leg Heat Therapy in Elderly Individuals Phase 2
Completed NCT04894929 - Comprehensive Geriatric Assessment in the Monitoring of Functional Improvement N/A
Not yet recruiting NCT06071130 - Emotion, Aging, and Decision Making N/A
Enrolling by invitation NCT04641663 - Multi-target Dietary Supplement Tolerability in an Aging Population (MTDSST) N/A
Completed NCT04088006 - The Evaluation of Efficacy and Safety of Hyaluronic Acid Injection on Skin Moisturization and Elasticity N/A
Completed NCT03695081 - Patient Pathway Pharmacist - Optimal Drug-related Care N/A
Recruiting NCT05424263 - Acetate and Age-associated Arterial Dysfunction Phase 2
Completed NCT05601713 - Mitigating Heat-induced Physiological Strain and Discomfort in Older Adults Via Lower Limb Immersion and Neck Cooling N/A
Completed NCT04551339 - Zinc Versus Multivitamin Micronutrient Supplementation in the Setting of COVID-19 N/A
Recruiting NCT04997577 - Speech Perception and High Cognitive Demand N/A
Completed NCT05922475 - Efficacy of Pre-sleep or Post-exercise Protein During 12 Weeks of Resistance Exercise Training N/A
Completed NCT04015479 - Peanut Protein Supplementation to Augment Muscle Growth and Improve Markers of Muscle Quality and Health in Older Adults N/A